Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

405

Participants

Timeline

Start Date

January 25, 1994

Primary Completion Date

August 15, 2011

Study Completion Date

January 6, 2012

Conditions
Hodgkin Lymphoma
Interventions
BIOLOGICAL

bleomycin sulfate

10 units/m2

DRUG

dacarbazine

375mg/m2

DRUG

doxorubicin hydrochloride

25mg/m2

DRUG

vinblastine

6mg/m2

RADIATION

radiation therapy

35Gy in 20 fractions (daily)

Trial Locations (22)

25123

Instituto del Radio O. Alberti Spedali Civili, Brescia

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V8R 6V5

BCCA - Vancouver Island Cancer Centre, Victoria

E1C 8X3

The Vitalite Health Network - Dr. Leon Richard, Moncton

E2L 4L2

Regional Health Authority B, Zone 2, Saint John

A1B 3V6

Dr. H. Bliss Murphy Cancer Centre, St. John's

B3H 1V7

QEII Health Sciences Centre, Halifax

P3E 5J1

Health Sciences North, Greater Sudbury

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

L5M 2N1

Trillium Health Partners - Credit Valley Hospital, Mississauga

L3Y 2P9

Stronach Regional Health Centre at Southlake, Newmarket

L1G 2B9

Lakeridge Health Oshawa, Oshawa

P6B 0A8

Algoma District Cancer Program, Sault Ste. Marie

M3M 0B2

Humber River Hospital, Toronto

M5G 1X5

Sinai Health System, Toronto

M5G 2M9

University Health Network, Toronto

H1T 2M4

CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal

S4T 7T1

Allan Blair Cancer Centre, Regina

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

06122

Policlinico Monteluce/Univ. Degli Studi Di Perugia, Perugia

SO14 0YG

Royal South Hants Hospital, Southampton

Sponsors
All Listed Sponsors
collaborator

Eastern Cooperative Oncology Group

NETWORK

lead

NCIC Clinical Trials Group

NETWORK